Lithium Pharmacology and Mechanism of Action

Lithium is a monovalent cation and the archetypal mood stabilizer, reintroduced to psychiatry by John Cade in 1949 and still regarded as a reference agent for the maintenance treatment of bipolar disorder. Unlike most psychotropic drugs, it is a simple ion rather than a complex organic molecule, and its therapeutic actions are attributed to interference with intracellular signaling cascades rather than to receptor antagonism.

Definition

Lithium is a monovalent alkali-metal cation used therapeutically (usually as the carbonate or citrate salt) as a mood stabilizer, exerting effects through modulation of intracellular second-messenger systems rather than through a defined neurotransmitter receptor.

Scope

This entry covers lithium's basic pharmacology as a small monovalent cation, the leading hypotheses for its molecular mechanism (phosphoinositide depletion and inhibition of glycogen synthase kinase-3), its narrow therapeutic index, and the evidence base for its mood-stabilizing and anti-suicidal effects. It is a pharmacological reference, not a guide to prescribing or monitoring.

Core questions

• How does a simple cation produce a mood-stabilizing effect?
• What are the phosphoinositide-depletion and GSK-3 hypotheses of lithium action?
• Why does lithium have a narrow therapeutic index requiring monitoring?
• What is the evidence for lithium's effect on suicide risk?

Key concepts

• Monovalent cation pharmacology
• Inositol monophosphatase inhibition
• Glycogen synthase kinase-3 (GSK-3) inhibition
• Narrow therapeutic index
• Renal clearance and dependence on sodium/water balance
• Anti-suicidal effect signal

Key theories

Inositol-depletion (phosphoinositide) hypothesis

Lithium uncompetitively inhibits inositol monophosphatase, lowering free myo-inositol and dampening phosphoinositide-mediated second-messenger signaling, proposed as a unifying account of its neural and developmental actions.

Glycogen synthase kinase-3 (GSK-3) inhibition hypothesis

Lithium inhibits GSK-3 both directly and indirectly, altering downstream pathways linked to circadian regulation, neuroplasticity, and cellular resilience; in vivo evidence supports GSK-3 inhibition in brain.

Mechanisms

Lithium is absorbed as a cation, distributes in total body water, is not protein-bound or metabolized, and is cleared almost entirely by the kidney, which underlies its sensitivity to sodium and fluid balance and its narrow therapeutic index (Malhi 2013). Its mood-stabilizing mechanism is not fully established. Two leading and complementary hypotheses dominate the literature: uncompetitive inhibition of inositol monophosphatase, which depletes free inositol and attenuates phosphoinositide signaling (the inositol-depletion hypothesis of Berridge and colleagues), and inhibition of glycogen synthase kinase-3, which modulates downstream pathways implicated in neuroplasticity, circadian rhythm, and cell survival (Malhi 2013). These converge on intracellular signaling and gene expression rather than on a single neurotransmitter receptor.

Clinical relevance

Lithium is described in guidelines and syntheses as a first-line maintenance agent in bipolar disorder, with evidence that it reduces recurrence of mood episodes and a meta-analytic signal that it lowers suicide and all-cause mortality compared with placebo in mood disorders (Cipriani 2013; Geddes 2013). Because its therapeutic and toxic concentrations are close, its clinical use involves serum monitoring; this entry describes that pharmacological property without providing dosing or monitoring instructions.

Evidence & guidelines

Systematic review and meta-analysis indicate that lithium reduces the risk of suicide and self-harm in mood disorders relative to placebo (Cipriani 2013), and narrative syntheses and guidelines position it as a reference maintenance treatment for bipolar disorder (Geddes 2013).

History

John Cade's 1949 observation that lithium salts calmed manic excitement reintroduced the ion into psychiatry after earlier nineteenth-century uses (Cade 1949). Mechanistic understanding advanced with Berridge and colleagues' 1989 inositol-depletion hypothesis linking lithium to phosphoinositide signaling (Berridge 1989), and subsequent work extended the picture to glycogen synthase kinase-3 and downstream neuroplastic pathways (Malhi 2013).

Debates

Which mechanism best explains lithium's mood-stabilizing action?

The inositol-depletion and GSK-3 inhibition hypotheses each have supporting evidence, and it remains unresolved whether one predominates, whether they act in concert, or whether additional pathways are required to explain the clinical effect.

Key figures

• John Cade
• Michael Berridge
• Gin Malhi
• Andrea Cipriani

Seminal works

• cade-1949
• berridge-1989
• malhi-2013
• cipriani-2013

Frequently asked questions

Does lithium act on a neurotransmitter receptor?

No. Lithium is a monovalent cation whose effects are attributed to modulation of intracellular second-messenger systems, such as the phosphoinositide cycle and glycogen synthase kinase-3, rather than to blocking or activating a specific neurotransmitter receptor.

Why is lithium said to have a narrow therapeutic index?

Lithium is cleared by the kidney and its therapeutic serum concentrations lie close to concentrations associated with toxicity, so the range between effective and harmful levels is small; this is a pharmacological property and not prescribing advice.